Last edition
News about "oncology portfolio "
Cipla Partners with Qilu to Bring Pembrolizumab Biosimilar to US Market
Cipla and Qilu Pharmaceutical partner to commercialise QL2107, a pembrolizumab biosimilar, in the US, strengthening Cipla’s oncology and biosimilars portfolio.
Oncology Portfolio | 04/09/2026 | By News Bureau | 100
Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma
Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.
Oncology Portfolio | 17/12/2025 | By News Bureau | 309
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy